EC Number   |
Application |
Reference |
|---|
   2.3.1.7 | analysis |
determination of free and total carnitine in plasma by an enzymatic reaction and spectrophotometric quantitation spectrophotometric determination of carnitine. the detection limit is 0.0017 mM/l in plasma |
673112 |
| 2.3.1.7 | analysis |
enzyme in pure form facilitates assay of carnitine and its acyl derivatives in tissues |
487397 |
| 2.3.1.7 | analysis |
in medicine and biochemical practice, the enzyme isolated from breast muscle is used analytically |
487405 |
| 2.3.1.7 | analysis |
paper chromatography-based assay for the detection of acetylcholine and L-acetylcarnitine. The assay can be used to measure both choline acetyltransferase and carnitine acetyltransferase activity in the same samples |
720292 |
| 2.3.1.7 | analysis |
specific activity is higher than in commercial preparations from other sources, enzyme prepared from yeast may be used for determination of carnitine in biological materials, this preparation is free of acetyl-CoA-deacetylase activity |
487405 |
| 2.3.1.7 | food industry |
modulating aroma compounds during wine fermentation by manipulating carnitine acetyltransferases in Saccharomyces cerevisiae |
673746 |
| 2.3.1.7 | medicine |
- |
487416 |
| 2.3.1.7 | medicine |
CAT is clinically used in evaluating L-CA and its esters in body fluids and tissues |
487421 |
| 2.3.1.7 | medicine |
CRAT function is not the major contributor to primary insulin resistance in cultured myotubes obtained from obese type 2 diabetes mellitus patients. mRNA levels and protein abundance of CRAT are similar between from obese persons with or without type 2 diabetes mellitus and lean controls. Of 14 different acylcarnitine species measured, the levels of palmitoylcarnitine and octadecanoylcarnitine are slightly reduced in myotubes derived from type 2 diabetes mellitus patients compared to glucose-tolerant obese and lean controls |
755931 |
| 2.3.1.7 | medicine |
dysregulation of the enzyme can lead to serious diseases in humans, inherited deficiency in CRAT activity can lead to neurological and heart problems, patients suffering from Alzheimer 's disease also have reduced CRAT activity, promising target for therapeutic development against several human diseases like diabetes |
487433 |
